

**FORM-2**

**THE PATENT ACT, 1970  
(39 OF 1970)  
AND  
THE PATENT RULES, 2003  
(As Amended)**

**COMPLETE SPECIFICATION  
(See section 10; rule 13)**


**"ANTI-VIRAL COMPOUNDS"**

**AbbVie Bahamas Ltd., a corporation organized and existing under the laws of The Bahamas,  
of Sassoon House, Shirley Street & Victoria Avenue, New Providence, Nassau The Bahamas.**

The following specification particularly describes the invention and the manner in which it is to be performed:

**We Claim:**

1. Methyl {(2*S*,3*R*)-1-[(2*S*)-2-{5-[(2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}-5-(6-fluoro-2-{(2*S*)-1-[*N*-(methoxycarbonyl)-*O*-methyl-L-threonyl]pyrrolidin-2-yl}-1*H*-benzimidazol-5-yl)pyrrolidin-2-yl]-6-fluoro-1*H*-benzimidazol-2-yl]pyrrolidin-1-yl]-3-



methoxy-1-oxobutan-2-yl}carbamate ( , or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising methyl {(2*S*,3*R*)-1-[(2*S*)-2-{5-[(2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}-5-(6-fluoro-2-{(2*S*)-1-[*N*-(methoxycarbonyl)-*O*-methyl-L-threonyl]pyrrolidin-2-yl]-1*H*-benzimidazol-5-yl)pyrrolidin-2-yl]-6-fluoro-1*H*-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate.
3. A compound as claimed in claim 1 or 2 as and when used in the preparation of a medicament for treating a patient infected with HCV, comprising an effective amount of the said compound or a pharmaceutically acceptable salt thereof, to said patient.

Dated this 12<sup>th</sup> day of February, 2013

(Archana Shanker)

Of Anand and Anand Advocates  
Agent for the Applicant

## **ABSTRACT**

### **"ANTI-VIRAL COMPOUNDS"**

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.